New considerations for macrolides, azalides, streptogramins, and ketolides:
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
New York [u.a.]
Dekker
2000
|
| Series: | Infectious disease and therapy
23 |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | 784 S. Ill. |
| ISBN: | 0824761391 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV012805723 | ||
| 003 | DE-604 | ||
| 005 | 20000119 | ||
| 007 | t | ||
| 008 | 991011s2000 a||| |||| 00||| eng d | ||
| 020 | |a 0824761391 |9 0-8247-6139-1 | ||
| 035 | |a (OCoLC)633753505 | ||
| 035 | |a (DE-599)BVBBV012805723 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 084 | |a XI 3505 |0 (DE-625)152997:12911 |2 rvk | ||
| 245 | 1 | 0 | |a New considerations for macrolides, azalides, streptogramins, and ketolides |c ed. by Stephen H. Zinner ... |
| 264 | 1 | |a New York [u.a.] |b Dekker |c 2000 | |
| 300 | |a 784 S. |b Ill. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Infectious disease and therapy |v 23 | |
| 650 | 0 | 7 | |a Makrolide |0 (DE-588)4168683-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Streptogramine |0 (DE-588)4183666-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Makrolide |0 (DE-588)4168683-4 |D s |
| 689 | 0 | 1 | |a Streptogramine |0 (DE-588)4183666-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Zinner, Stephen H. |e Sonstige |4 oth | |
| 830 | 0 | |a Infectious disease and therapy |v 23 |w (DE-604)BV001854049 |9 23 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008709780&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-008709780 | ||
Record in the Search Index
| _version_ | 1804127478111797248 |
|---|---|
| adam_text | Contents
Series Introduction m
Preface v
Contributors xxiii
Tributes to Harold C. Neu, M.D. xxvii
Parti State of the Art Reviews
1.1 Linking Pharmacodynamics with Pharmacokinetics
(Including Comments on CO2 and Susceptibility
Testing) 3
Fiona J. Boswell and Richard Wise
1.2 Drug Interactions with Macrolides and Related
Structures 25
Larry Mole
1.3 Resistance to MASK: Mechanisms and Potential
Solutions 35
Jacques F. Acar
1.4 Macrolides, Azalides, and Streptogramins in Patients
with Hepatic and Renal Failure 45
Oksana M. Korzeniowski
1.5 Atherosclerosis 53
Gerardo E. Bozovich and Enrique P. Gurfinkel
1.6 Chronic Chlamydia pneumoniae Infections 61
J. Thomas Grayston
vHi Contents
Part II Pharmaceutical Company Updates
n.l Pharmaceutical Company Updates 69
J Carl Craft
n.2 Ketolide: Novel Antibacterial Agent Designed
to Overcome Erythromycin A Resistance 79
Andre Bryskier, C.Agouridas, andJ. F. Chantot
n.3 The Artemis Project: A Global Surveillance Study 103
Dennis R. Pontani and Glenda M. Treadway
n.4 Research in Streptogramins 109
Bruce Kreter and Michael Dowzicky
Part III Workshop Seminars Summaries and Relevant
Extended Abstracts
Workshop 1
III.l Ketolides and Other Macrolide Derivatives 121
Claude Carbon and Lowell S. Young
Extended Abstracts
1.08 Susceptibility of Erythromycin Sensitive and
Erythromycin Resistant Staphylococci,
Enterococci, and Pneumococci to HMR 3004
and Four Macrolides 125 *
J. M. T. Hamilton Miller and S. Shah
1.11 In Vivo Antibacterial Activity of HMR 3647,
a New Ketolide Highly Active against Respiratory
Pathogens 131
Alain Bonnefoy
1.12 In Vitro Antibacterial Activity of HMR 3647,
a New Ketolide Highly Active against Respiratory
Pathogens 135
J. F. Chantot
1.14 HMR 3647 in the Treatment of Bacteroides
fragilis Experimental Abdominal Abscess 142
H. Thadepalli, S. K. Chuah, S. Qazi, C. I
Thadepalli, F. Thadepalli, andS. Gollapudi
Contents
1.16 In Vitro Activity of a New Ketolide Antibiotic,
HMR 3647, against Chlamydia pneumoniae 146
Patricia M. Roblin and Margaret R.
Hammerschlag
1.23 Similarities and Differences in Ketolide
and Macrolide Interaction within Two Distinct
Domains of 23S Ribosomal RNA 150
P. Collette, S. Douthwaite, A. Mankin,
and P. Mauvais
1.29 Synthesis of Novel Dihydro and Tetrahydro
Desmycosin Derivatives, 13 Hydroxy
Desmycosin Oximes 157
Amalia Naranda, Nevenka Lopotar,
and Zeljko Kelnerid
Workshop 2
IQ.2 Vancomycin Resistant Enterococci: Summary
Comments 163
Barbara E. Murray and John E. McGowan, Jr.
Extended Abstracts
2.02 Quinupristin/Dalfopristin (Synercid) Activity
and Spectrum from a 1997 Study in Over 200
Medical Centers: Analysis for Regional Variations,
Coresistance, and Validity of Proposed Susceptible
Breakpoints 171
Ronald N. Jones, Charles H. Ballow, Douglas
Biedenbach, Jerome J. Schentag, and the
SMART Study Group
2.03 Spanish Multicenter Study of the In Vitro Activity
of Quinupristin/Dalfopristin (Synercid) 177
D. Ddmaso, V. Ausina, F. Baquero, R. Cisterna,
J. A. Garcia Rodriguez, M. Gobemado, R.
G6mez Lus, J. Linares, I. Losada, F. Lueiro,
E. Perea, J. Prieto, F. Soriano, A. Nevado,
C. Feger, L. Herrera, and I. Farr
x Contents
2.09 Azalide and Macrolide Resistance Among Recent
Clinical Isolates of Gram Positive Bacteria from
Ten North American Medical Centers 184
Peter C. Fuchs, Arthur L. Barry,
and Steven D. Brown
2.12 Quinupristin/Dalfopristin Resistance in Glycopeptide
Resistant E. faecium: The Link to Animal Husbandry 191
G. Werner, I. Klare, and W. Wtte
Workshop 3
III.3a Resistance to Macrolides Lincosamides Streptogramins
and Ketolides in Staphylococci and Streptococci,
and New Therapeutic Strategies 197
Philippe Moreillon
m.3b Other Resistant Gram Positive Organisms (Penicillin
Resistant Pneumococci, Streptococci) 209
Peter Appelbaum
Extended Abstracts
3.05 Antibiotic Susceptibility of Penicillin Resistant
Streptococcus pneumoniae 217
Z Samra, O. Ofir, Y. Michalevitch, M. Yardeni,
B. Lev, and S. Harrari
3.06 In Vitro Susceptibility of Bacteremic
Pneumococcal Isolates to Penicillin
and Erythromycin, 1992 1996 222
Glenn S. Turett, Anita Y. Lui, and Jay Ward
Kislak
3.07 Susceptibility of Adult and Pediatric Isolates
of Streptococcus pneumoniae from Midwestern
Community Hospitals 228
Charles E. Edmiston, Eileen Matthews,
Ralph C. Gordon, and William G. Jochimsen
3.08 In Vitro Activity of Roxithromycin Compared to
Azithromycin, Ciprofloxacin, Levofloxacin,
Ceftriaxone, and Penicillin against 222
Contents xj
Streptococcus pneumoniae Strains Isolated
in Argentina 233
G. Tome, J. M. Casellas, M. Gilardoni,
and G. Pagniez
3.10 MLS Phenotypes and Mechanisms
of Resistance in Streptococcus pneumoniae 237
A. Portillo, M. Lantern, U. J. Gastanares,
F. Ruiz Larrea, M. Zarazaga, I. Olarte,
and C. Torres
3.14 Comparison of Resistance Emergence Rates
in Streptococcus pneumoniae Following
Exposure to Subinhibitory or Higher
Concentrations of Azithromycin, Ampicillin,
or Cefaclor 243
Judith M. Hyatt and Jerome J. Schentag
3.18 Macrolide Resistance Among 5. pneumoniae
Isolates in Italy 250
Giuseppe Cornaglia, Giuliana Lo Cascio,
Laura Masala, The Italian Surveillance Group
for Antimicrobial Resistance, and Roberta
Fontana
3.21 Susceptibility to Quinupristin/Dalfopristin
in MRS A from Nationwide Surveillance
in Germany 255
W. Witte, C. Cuny, and C. Braulke
3.23 In Vitro Activity of Streptogramins against 45
Methicillin Resistant Staphylococcus aureus
with Decreased Susceptibility to Dalfopristin 260
L Gazagne, P. Gueudet, E. Lecaillon, A. he
Coustumier, and R. Bismuth
3.24 In Vitro Activity of Quinupristin Dalfopristin in
Comparison to Other Antibiotics against
Staphylococci from Patients with Bacteremia:
First Results of a German Multicenter Study 268
Christofvon Eiffi Ralf Rene Reinert, and Georg
Peters, for the German MA.R.S. Study Group
xii Contents
Workshop 4
III.4 Novel Uses of Macrolides, Azalides, Streptogramins,
and Ketolides in Treating Emerging Pathogens 277
Thomas J. Marrie
Extended Abstracts
4.02 Clarithromycin: Effect of a New Macrolide
Antibiotic on a Transplanted Tumor in Rats 283
Kazuhiko Sassa, Yutaka Mizushima, Takashi
Fujishita, Rokuo Oosaki, and Masashi
Kobayashi
4.07 Electron Microscopy Study of Chlamydia
pneumoniae and Atherosclerosis: The Importance
of Macrolides 293
P. Ramos, F. Ortega, R. Diaz de Otazu,
and J. Samaniego
4.08 Chlamydia pneumoniae Lives in Most
Atherosclerotic Lesions 297
C. C. Kuo, J. T. Grayston, L A. Campbell,
L. Jackson, andS. P. Wang
4.09 In Mouse Models of Atherosclerosis
and C. pneumoniae Infection, Macrophages
Mediate Dissemination of C. pneumoniae
to Atheromas 302
L. A. Campbell, T. C. Moazed, C. C. Kuo,
and J. T. Grayston
4.12 Chlamydia pneumoniae IgG Antibodies
Following Cardiac Surgery 308
R. B. Kundsin, J. Fang, and S. A. Poulin
4.17 Effect of Clarithromycin on Neutrophil
Migration Through the Airway Epithelial
Cell Monolayers and IC AM 1 Expression 313
K. Isono, J. Tamaoki, K. Nishimura, E. Tagaya,
M. Kondo, and A. Nagai
4.18 Effects of Clarithromycin on Inducible Nitric
Oxide Synthase Gene Expression in Rat Alveolar
Contents
Macrophages and Nitric Oxide Concentration
in Exhaled Air 319
/ Tamaoki, K. Kohri, E. Tagaya, M. Kondo,
and A. Nagai
4.26 Antibiotic Susceptibility Testing of Ureaplasma
urealyticum 324
Erika Ddsa, Elizabeth Nagy, Wolfgang Folk,
and Uwe Bailies
4.33 Modification of Fecal Flora after Long Term
Administration of Roxithromycin,
Clarithromycin, or Azithromycin to Adult
Volunteers 330
J. M. Casellas, G. Tome, M. Gilardoni,
G. Pagniez, and A. Farinati
4.34 Randomized Trial of Azithromycin vs.
Ciprofloxacin for Treatment of Typhoid Fever
in Egypt 336
Nabill. Girgis, Forrest M. Brown,
David Tribble, and Thomas Butler
4.35 Treatment of Typhoid Fever in a Randomized
Multicenter Trial in India: A Comparison
of Azithromycin and Chloramphenicol 341
Thomas Butler, C. B. Sridhar, M. K. Daga,
Kamal Pathak, R. B. Pandit, Rasik Khakhria,
ChandrashekharN. Potkar, Michael T. Zelasky,
and Raymond B. Johnson
4.36 Susceptibility of Anaerobic Bacteria to
Azithromycin Determined by Common Method
and in Oxyrase System 348
Ildikd Szoke, Erika Ddsa, and Elizabeth Nagy
4.39 Quantitative Analysis of Free Fatty Acid in the
Sebum of Acne Patients Treated with
Roxithromycin 356
H. Akamatsu, I. Kurvkawa, H. Iba, S. Nishijima,
and T. Horio
4.40 Pulse Azithromycin Is Effective in Inflammatory
AcneVulgaris 362
i; Boni E. Elewski
xlv Contents
4.43 Side Effects of 4.5 g Azithromycin Given
Over 9 Days 367
Franc Strle, Vera Maraspin, Stanka Lotrid
Furlan, Joze Cimperman, TomalJurca, and
Mateja Logar
AM Azithromycin Compared to Clarithromycin,
Roxithromycin, and Erythromycin against
Pasteurella multocida and Other Pasteurella
Species 372
Ellie J. C. Goldstein and Diane M. Citron
A.A1 Azithromycin in the Therapy of Ulceroglandular
Tularemia 376
Adrienne Ferencz
4.48 In Vitro Activity of Azithromycin against
Acinetobacter Strains Resistant to Routinely
Tested (J Lactams, Aminoglycosides,
Quinolones, and Imipenem 382
Diane M. Citron and Maria D. Appleman
4.51 Azithromycin vs. Penicillin V in Combination
with Ofloxacin and Fluconazole for Prophylaxis
of Infection in Neutropenic Patients with
Leukemia 388
V. Krcmery, T. Kollar, S. Spanilc, J. Nogova, I.
Krupova, and I. Svetlansky
Workshop 5
III.5 Use of the Newer Macrolide, Azalide, Streptogramin,
and Ketolide Antibiotics for Mycobacterial and Other
HIV Related Diseases 393
Kenneth H. Mayer and Nathan Clumeck
Extended Abstracts
5.03 Serum and Leukocyte Pharmacokinetics
of Azithromycin After Multiple Oral Doses 405
G. Foulds, O. Kuye, B. Boris, G. Wei, and S. H.
Preskorn
5.05 Lack of Pharmacokinetic Interaction Between
Azithromycin and Fluconazole 411
r* r? ij. r w i « — —
Contents ;cv
Workshop 6
in.6 Use of Macrolides and Azalides in Pediatrics 419
George H. McCracken, Jr. and Jerome O. Klein
Extended Abstracts
6.03 Clinical Picture and Treatment of Chlamydial
Infection in the Early Neonatal Period 423
/. /. Evsiukova and A. M. Savitcheva
6.05 Acquisition of Ureaplasma urealyticum from
the Maternal Genital Tract Implicated in
Respiratory Tract Infections of Young Children 428
R. B. Kundsin, R. D. DeLollis, and S. A. Poulin
6.06 Ureaplasma urealyticum and Reactive Airway
Disease in Young Children 433
R. D. DeLollis, R. B. Kundsin, andS. A. Poulin
6.07 Erythromycin Estolate vs. Amoxicillin for Acute
Otitis Media with Effusion: A Double Blind
Randomized Trial 437
Horst Scholz, RainerNoack, Martin Dornseiff,
and the AOM Study Group
6.09 Comparative Efficacy of Clarithromycin
and Amoxicillin in the Treatment of Venezuelan
Children with Acute Otitis Media 442
J. R. Torres, A. Ortiz, T. Suarez, andM. Angeli
Greaves
6.15 Azithromycin vs. Clarithromycin: Efficacy
and Safety in the Treatment of Acute Otitis
Media in Children 447
Ivo Slapdk, Pavel Hornflc, and Jan Dezort
6.18 Susceptibility of Streptococcus pyogenes to
Erythromycin and Clarithromycin in Childhood
Pharyngotonsillitis in Spain 451
/. Garcia de Lomas, C. Gimeno, J. Diez,
M. Bermejo, M. Calvillo, and the Spanish
Collaborative Group for the Surveillance of
Resistance to Macrolides in Primary Care
xvi Contents
6.25 Tolerance to Penicillin and Persistence of
Streptococcus pyogenes in Childhood
Pharyngotonsillitis in Spain 457
J. Garcia de Lomas, A. Farga, C. Gimeno,
J. Diez, M. Bermejo, M. Calvillo, and the Spanish
Collaborative Group for the Surveillance of
Resistance to Macrolides in Primary Care
6.26 How Frequently Does Mycoplasma Cause
Pneumonia? 463
J. A. Gdmez Campderd, R. Rodriguez
Ferndndez, S. C. Ramos Lopez, M. L. Navarro
Gomez, A. Cristina De La Torre, M. Ldpez
Gomez, A. Casanova Morcillo, and
M. I. Gonzalez Sanchez
6.29 Three Day Azithromycin vs. 10 Day
Co Amoxiclav in the Treatment of Community
Acquired Pneumonia in Children 470
L. Stratchounski, L. Jarcova, L. Tsybina,
andM. Kvirkvelia
Workshop 7
III.7 Gastritis and Peptic Ulcer 477
Manuel Lopez Brea and Francis Megraud
Extended Abstracts
7.09 In Vitro Activity of Clarithromycin against
Intracellular Helicobacter pylori 487
R. Piccolomini, G. Di Bonaventura, G. Catamo,
and M. Neri
7.14 Global Relevance of Resistance to
Clarithromycin and Metronidazole in the
Treatment of Helicobacter pylori Infection 492
Stuart L. Hazell
7.15 Clinical Resistance to Erythromycin
and Clarithromycin in Helicobacter pylori
Contents ^a
Associated with Mutations in the 23S rRNA
Gene 498
M. Isabel Garcia Arata, Fernando Baquero,
Luis de Rafael, Carlos Martin deArgila, Javier
P. Gisbert, Fernando Bermejo, Daniel Boixeda,
and Rafael Cantdn
7.45 Azithromycin and Omeprazole with or without
Tinidazole in the Eradication of Helicobacter
pylori 503
B. Vucelic, N. Rustemovid, T. Brkit, J. Culig, and
D. Pavid Sladoljev
7.47 Synergistic Effect of Azithromycin
and Tinidazole in Eradicating Helicobacter
pylori 5O8
R. E. A. Seelis and W. Dohmen
Workshop 8
III.8 Sexually Transmitted Diseases/Chlamydia
and Ocular Infections 517
Smilja Kalenic and Margaret R. Hammerschlag
Extended Abstracts
8.01 Comparative In Vitro Activity of Macrolides,
Minocycline, and Quinolones against Chlamydia
spp. in Different Cell Lines 535
Manuela Donati, Fabio Rurnpianesi, Marcelo
Rodriguez Fermepin, Federico Marchetti,
and Roberto Cevenini
8.03 Effects of Long Term Administration
of Roxithromycin on Neutrophil Count
and Interleukin 8 Level in Endometrial Cavity
Subjected to Pyometra 5^0
Toshiya Ito, Koji Izumi, Hiroshige Mikamo,
Kyoko Kawazoe, and Teruhiko Tamaya
8.04 Infertility in Women Who Have Ureaplasma
urealyticum Infection f47
Rita D. DeLollis, Sharon A. Poulin, and Ruth B.
Kundsin
xviii Contents
8.07 Effectiveness and Safety Study of
Roxithromycin (Rulid) Administration
in the Treatment of Nongonococcal
Genitourinary Infections 551
C. Osuna, R. Di Domenico, J. Otero, J. F. Uribe,
G. S. Restrepo, M. C. Arturo, L. Valderrama,
M. T. Yancis, K. Morillo, B. Bojanini,
E. Morillo, E. Price, C. Prado, G. Uriza,
S. Capasso, R. Navas, H. Novas, F. Vergara,
J. Pedraza, and A. Alviar
8.11 Single Dose Azithromycin vs. a 7 Day Course
of Doxycycline for the Empirical Treatment
of Cervicitis in an Urban Emergency
Department: A Prospective, Randomized Trial
and Cost Effectiveness Analysis 557
Peggy S. McKinnon, Elizabeth A. Lyons, Roy C.
Elrod, and Robert Welch
8.14 Treatment of Neonatal Chlamydial
Conjunctivitis with Azithromycin 563
Margaret R. Hammerschlag, Maureen Gelling,
Patricia M. Roblin, Andrei Kutlin, and Jose E.
Me
8.15 Ocular Penetration of Oral Clarithromycin
in Humans 567
M. Badawi Al Sibai, Ali S. Al Kaff, Adnan
El Yazigi, and Dale Raines
8.17 Single Dose Azithromycin Treatment of
Chlamydia pneumoniae lnfected Respiratory
Cells in an In Vitro Model 573
Dorothy L. Patton, Yvonne T. Cosgrove Sweeney,
Maricela V. Pier, and Cho Chou Kuo
8.19 Chlamydia pneumoniae (TWAR) as a Cause
of Community Acquired Pneumonia in Adults:
Laboratory Diagnosis, Population Prevalence
Antibody, and Response to Antibiotic Therapy 578
San Ping Wang, Lee Ann Campbell, William W.
Gregory, Cho Chou Kuo, andJ. Thomas
Grayston
Contents
XIX
8.19a Microimmunofluorescence Test for Chlamydia
pneumoniae Serology 5g5
San Ping Wang
8.27 Effects of Clarithromycin on Neutrophil Count
and Interleukin 8 Level in Endometrial Cavity
Subjected to Uterine Endometritis 592
Koji Izumi, Toshiya ho, Hiroshige Milcamo,
Kyoko Kawazoe, and Teruhiko Tamaya
Workshop 9
III.9 Introduction—Acute Otitis Media—Group A
Streptococcal Pharyngitis 601
Robert Cohen
Extended Abstracts
9.11 Pharmacodynamics of Dirithromycin in Tonsils 607
E. Bergogne Bire zin, C. Muller Serieys,
E Danon, E Lemattre, G. Gehanno, and
M. Derriennic
9.14 Effect of Macrolide Therapy on S. pneumoniae
Specific Mononuclear Cell Cytokine and Nitric
Oxide Production in Acute Sinusitis 614
Luis Jaimez, Shi Y. Lai, Soo Fang Wang, Chin
M. Chu, S. Rockitter, and Marianne Frieri
9.15 Clinical Relevance of Macrolide Resistance of
Group A Streptococci in Italy 622
Nicola Principi, Paola Marchisio, and the
Italian Study Group for the Clinical Relevance
of Macrolide Resistance of Group A Streptococci
9.23 Clarithromycin in the Treatment of Acute
Infections of the Airways: Results from
a Multicenter Clinical Study 628
Ludmila Vyhndnkovd
9.24 Clarithromycin for the Treatment of Respiratory
Tract Infections: A Slovak Pilot Study 632
/. Krupova, P. Jarcuska, G. Gemesova,
J. Novotny, A. Demitrovicova, V. Krcmery,
E. Morova, andJ. Skoupa
xx Contents
9.29 Low Dose Long Term Macrolide Therapy
for Foreign Body Sensation in the Throat 635
Hayato Misawa, Toshinori Iwagaki, and Yukari
Ohmori
Workshop 10
ni.10 Lower Respiratory Tract Infections: Pneumonia 643
Hartmut Lode and Victor L. Yu
Extended Abstracts
10.03 Comparison of Azithromycin, Trovafloxacin,
and Ceftriaxone for Pneumococcal Pneumonia
in Ethanol Fed Rats 649
Laurel C. Preheim, Mei Yue, Mary U. Snitily,
Martha J. Gentry, and Keith M. Olsen
10.07 Comparison of Bactericidal Activity after Single
and Multidose Administration of Clarithromycin,
Azithromycin, and Cefuroxime Axetil against
Streptococcus pneumoniae 653
Melinda K. Lacy, Robert C. Owens, Jr., Xiawei
Xu, David P. Nicolau, Richard Quintiliani, and
Charles H. Nightingale
10.10 Phase I Determination of Azithromycin in
Plasma During a 6 Week Period in Normal
Volunteers after Intake of a Standard Dose
of 500 mg Once Daily for 3 Days 658
P. Cauchie, A. Hubloux, and F. Crokaert
10.18 Tolerability of Roxithromycin vs. Erythromycin
in Patients with Lower Respiratory Tract
Infections 664
Richard J. Milne, Roger Olney, Gregory D.
Gamble, and John Tumidge
10.21 Pharmacoeconomic Method to Assess the Cost
Effectiveness of Antibiotic Treatment of
Community Acquired Pneumonia 674
Joseph A. Paladino, Larry D. Gudgel, and
Michael S. Niederman
Contents ^
Workshop 11
III. 11 Lower Respiratory Infections: Chronic Bronchitis 683
Mark Gotfried
Extended Abstracts
11.03 Activity of Azithromycin and Macrolides against
Recent Isolates of p Lactam Resistant
Haemophilus influenzae 691
M. Anderson, J. Retsema, and Dennis R. Pontani
11.10 Effects of Increased Macrolide Consumption
on Resistance to Erythromycin and
Azithromycin among Common Respiratory
Pathogens in Slovenia 695
Milan Cizman, Marko Pokorn, Katja Seme,
Andreja Oraiem, andMetka Paragi
11.17a Economics of Community Management of Acute
Bronchitis or an Acute Infectious Exacerbation
of Chronic Bronchitis 701
Richard J. Milne and Jon B. Wilcox
11.17b Roxithromycin vs. Erythromycin in the
Treatment of Acute Bronchitis and Acute
Exacerbations of Chronic Bronchitis:
A Pharmacoeconomic Threshold Analysis 711
Richard J. Milne
Workshop 12
Extended Abstract
12.09 Lack of Resistance Emergence to Azithromycin
as It Relates to Its Unique Pharmacokinetics 723
J. Retsema, A. Girard, andD. Williams
Author Index 729
Subject Index 733
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV012805723 |
| classification_rvk | XI 3505 |
| ctrlnum | (OCoLC)633753505 (DE-599)BVBBV012805723 |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01484nam a2200373 cb4500</leader><controlfield tag="001">BV012805723</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20000119 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">991011s2000 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0824761391</subfield><subfield code="9">0-8247-6139-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)633753505</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV012805723</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 3505</subfield><subfield code="0">(DE-625)152997:12911</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New considerations for macrolides, azalides, streptogramins, and ketolides</subfield><subfield code="c">ed. by Stephen H. Zinner ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York [u.a.]</subfield><subfield code="b">Dekker</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">784 S.</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Infectious disease and therapy</subfield><subfield code="v">23</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Makrolide</subfield><subfield code="0">(DE-588)4168683-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Streptogramine</subfield><subfield code="0">(DE-588)4183666-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Makrolide</subfield><subfield code="0">(DE-588)4168683-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Streptogramine</subfield><subfield code="0">(DE-588)4183666-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zinner, Stephen H.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Infectious disease and therapy</subfield><subfield code="v">23</subfield><subfield code="w">(DE-604)BV001854049</subfield><subfield code="9">23</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008709780&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-008709780</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV012805723 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:33:59Z |
| institution | BVB |
| isbn | 0824761391 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-008709780 |
| oclc_num | 633753505 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 784 S. Ill. |
| publishDate | 2000 |
| publishDateSearch | 2000 |
| publishDateSort | 2000 |
| publisher | Dekker |
| record_format | marc |
| series | Infectious disease and therapy |
| series2 | Infectious disease and therapy |
| spelling | New considerations for macrolides, azalides, streptogramins, and ketolides ed. by Stephen H. Zinner ... New York [u.a.] Dekker 2000 784 S. Ill. txt rdacontent n rdamedia nc rdacarrier Infectious disease and therapy 23 Makrolide (DE-588)4168683-4 gnd rswk-swf Streptogramine (DE-588)4183666-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Makrolide (DE-588)4168683-4 s Streptogramine (DE-588)4183666-2 s DE-604 Zinner, Stephen H. Sonstige oth Infectious disease and therapy 23 (DE-604)BV001854049 23 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008709780&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | New considerations for macrolides, azalides, streptogramins, and ketolides Infectious disease and therapy Makrolide (DE-588)4168683-4 gnd Streptogramine (DE-588)4183666-2 gnd |
| subject_GND | (DE-588)4168683-4 (DE-588)4183666-2 (DE-588)4143413-4 |
| title | New considerations for macrolides, azalides, streptogramins, and ketolides |
| title_auth | New considerations for macrolides, azalides, streptogramins, and ketolides |
| title_exact_search | New considerations for macrolides, azalides, streptogramins, and ketolides |
| title_full | New considerations for macrolides, azalides, streptogramins, and ketolides ed. by Stephen H. Zinner ... |
| title_fullStr | New considerations for macrolides, azalides, streptogramins, and ketolides ed. by Stephen H. Zinner ... |
| title_full_unstemmed | New considerations for macrolides, azalides, streptogramins, and ketolides ed. by Stephen H. Zinner ... |
| title_short | New considerations for macrolides, azalides, streptogramins, and ketolides |
| title_sort | new considerations for macrolides azalides streptogramins and ketolides |
| topic | Makrolide (DE-588)4168683-4 gnd Streptogramine (DE-588)4183666-2 gnd |
| topic_facet | Makrolide Streptogramine Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008709780&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV001854049 |
| work_keys_str_mv | AT zinnerstephenh newconsiderationsformacrolidesazalidesstreptograminsandketolides |